File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Asian clinical trials for new drug approval

TitleAsian clinical trials for new drug approval
Authors
KeywordsMedical sciences
Urology and nephrology
Issue Date2012
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJU
Citation
The 2012 Asia-Pacific Society of Uro-oncology Symposium held in conjunction with the 11th Asian Congress of Urology (ACU), Pattaya, Thailand, 22-26 August 2012. In International Journal of Urology, 2012, v. 19 suppl. 1, p. 422, abstract APSU25-04 How to Cite?
AbstractOne third of all industry sponsored phase III drug trial registered in the US trial registry are carried out in Asian. It significantly exceeded the proportion of non-industry sponsored drug trial in this area. With the driving force of the globalization, economic shift from the west to the east, relative the lack of investigators, patients etc. in established regions, Asia have nourished to become one of the most important global regions for drug trials. It is noted that the North East Asia represents more than two third of all industry-sponsored trial sites in Asia, in which most of them are phase II/III. It is predicted to become the most popular emerging clinical trial region in the coming years. In this presentation, some basic concepts of drug clinical trials will be elaborated. The current status of Asian drug clinical trials will also be discussed and analyzed. Hopefully this could provide some update on the recent situation and a more in-depth understanding to our own position in this aspect.
DescriptionAbstract and Invited Lecture
This journal suppl. entitled: Abstracts of the 11th Asian Congress of Urology of the Urological Association of Asia ... 2012
Persistent Identifierhttp://hdl.handle.net/10722/169386
ISSN
2015 Impact Factor: 1.878
2015 SCImago Journal Rankings: 0.841
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYiu, MKen_US
dc.date.accessioned2012-10-18T08:53:08Z-
dc.date.available2012-10-18T08:53:08Z-
dc.date.issued2012en_US
dc.identifier.citationThe 2012 Asia-Pacific Society of Uro-oncology Symposium held in conjunction with the 11th Asian Congress of Urology (ACU), Pattaya, Thailand, 22-26 August 2012. In International Journal of Urology, 2012, v. 19 suppl. 1, p. 422, abstract APSU25-04en_US
dc.identifier.issn0919-8172-
dc.identifier.urihttp://hdl.handle.net/10722/169386-
dc.descriptionAbstract and Invited Lecture-
dc.descriptionThis journal suppl. entitled: Abstracts of the 11th Asian Congress of Urology of the Urological Association of Asia ... 2012-
dc.description.abstractOne third of all industry sponsored phase III drug trial registered in the US trial registry are carried out in Asian. It significantly exceeded the proportion of non-industry sponsored drug trial in this area. With the driving force of the globalization, economic shift from the west to the east, relative the lack of investigators, patients etc. in established regions, Asia have nourished to become one of the most important global regions for drug trials. It is noted that the North East Asia represents more than two third of all industry-sponsored trial sites in Asia, in which most of them are phase II/III. It is predicted to become the most popular emerging clinical trial region in the coming years. In this presentation, some basic concepts of drug clinical trials will be elaborated. The current status of Asian drug clinical trials will also be discussed and analyzed. Hopefully this could provide some update on the recent situation and a more in-depth understanding to our own position in this aspect.-
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJU-
dc.relation.ispartofInternational Journal of Urologyen_US
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectMedical sciences-
dc.subjectUrology and nephrology-
dc.titleAsian clinical trials for new drug approvalen_US
dc.typeConference_Paperen_US
dc.identifier.emailYiu, MK: pmkyiu@hku.hken_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1442-2042.2012.03167.x-
dc.identifier.hkuros212264en_US
dc.identifier.volume19en_US
dc.identifier.issuesuppl. 1en_US
dc.identifier.spage422en_US
dc.identifier.epage422en_US
dc.identifier.isiWOS:000308130600002-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats